Please enable JavaScript.
Coggle requires JavaScript to display documents.
MSD TW Oncology - Coggle Diagram
MSD TW Oncology
Reimbursement
Base
Pan-lung
KN047 (TPS>1) Dec 2022
KN189 (TPS>1) Oct, 2023
HNSCC
KN048 (CPS>20) Dec 2022
Upside
HNSCC
KN048 (CPS>1), May 2023
Aspiration
MYMI Apr 2023
vs. Private: 2021 32%
2022 28%
2025 48%
Vision
TW Oncology Leader
1st MS in TW
2x revenue (120M USD)
3 Key indication for reumvyrsement (189/ 407/ 048)
Strategy focus
2025
LC, H&N and New Launches
Broaden reimbursement
Omni enagement and alliance
Talent & Excution
2022-23
Reimbursement in LC & H&N
Growth in private market & alliance
Execution excellence (digital, agile)
Policy shaping in IO funding